001     418120
005     20250729165648.0
024 7 _ |a 10.1021/acs.molpharmaceut.7b01022
|2 doi
024 7 _ |a 1543-8384
|2 ISSN
024 7 _ |a 1543-8392
|2 ISSN
024 7 _ |a pmid:29232147
|2 pmid
024 7 _ |a WOS:000424730900030
|2 WOS
024 7 _ |a altmetric:31915547
|2 altmetric
024 7 _ |a 10.3204/PUBDB-2019-00207
|2 datacite_doi
024 7 _ |a openalex:W2774297716
|2 openalex
037 _ _ |a PUBDB-2019-00207
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Ziller, Antje
|b 0
245 _ _ |a Incorporation of mRNA in Lamellar Lipid Matrices for Parenteral Administration
260 _ _ |a Washington, DC
|b American Chemical Society
|c 2018
336 7 _ |2 DRIVER
|a article
336 7 _ |2 DataCite
|a Output Types/Journal article
336 7 _ |0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|a Journal Article
|b journal
|m journal
|s 1547983912_9060
336 7 _ |2 BibTeX
|a ARTICLE
336 7 _ |2 ORCID
|a JOURNAL_ARTICLE
336 7 _ |0 0
|2 EndNote
|a Journal Article
500 _ _ |a © American Chemical Society
520 _ _ |a Insertion of high molecular weight messenger RNA (mRNA) into lyotropic lipid phases as model systems for controlled release formulations for the mRNA was investigated. Low fractions of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) were used as an anchor to load the mRNA into a lamellar lipid matrix. Dispersions of zwitterionic lipid in the aqueous phase in the presence of increasing fractions of mRNA and cationic lipid were prepared, and the molecular organization was investigated as a function of mRNA and cationic lipid fraction. Insertion of both cationic lipid and mRNA was clearly proven from the physicochemical characteristics. The d-spacing of the lipid bilayers, as determined by small-angle X-ray scattering (SAXS) measurements, responded sensitively to the amount of inserted DOTAP and mRNA. A concise model of the insertion of the mRNA in the lipid matrices was derived, indicating that the mRNA was accommodated in the aqueous slab between lipid bilayers. Depending on the DOTAP and mRNA fraction, a different excess of water was present in this slab. Results from further physicochemical characterization, including determination of free and bound mRNA, zeta potential, and calorimetry data, were in line with this assumption. The structure of these concentrated lipid/mRNA preparations was maintained upon dilution. The functionality of the inserted mRNA was proven by cell culture experiments using C2C12 murine myoblast cells with the luciferase-encoding mRNA. The described lipid phases as carriers for the mRNA may be applicable for different routes of local administration, where control of the release kinetics and the form of the released mRNA (bound or free) is required.
536 _ _ |0 G:(DE-HGF)POF3-6215
|a 6215 - Soft Matter, Health and Life Sciences (POF3-621)
|c POF3-621
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef
693 _ _ |0 EXP:(DE-H253)D-A2-20150101
|1 EXP:(DE-H253)DORISIII-20150101
|6 EXP:(DE-H253)D-A2-20150101
|a DORIS III
|f DORIS Beamline A2
|x 0
700 1 _ |a Nogueira, Sara S.
|b 1
700 1 _ |a Hühn, Eva
|b 2
700 1 _ |0 P:(DE-H253)PIP1002601
|a Funari, Sergio de Souza
|b 3
700 1 _ |a Brezesinski, Gerald
|b 4
700 1 _ |a Hartmann, Hermann
|b 5
700 1 _ |a Sahin, Ugur
|b 6
700 1 _ |a Haas, Heinrich
|b 7
700 1 _ |0 P:(DE-HGF)0
|a Langguth, Peter
|b 8
|e Corresponding author
773 _ _ |0 PERI:(DE-600)2132489-X
|a 10.1021/acs.molpharmaceut.7b01022
|g Vol. 15, no. 2, p. 642 - 651
|n 2
|p 642 - 651
|t Molecular pharmaceutics
|v 15
|x 1543-8392
|y 2018
856 4 _ |u https://bib-pubdb1.desy.de/record/418120/files/Langguth_RNA_SAXS_review_clean.pdf
|y Published on 2017-12-12. Available in OpenAccess from 2018-12-12.
|z StatID:(DE-HGF)0510
856 4 _ |u https://bib-pubdb1.desy.de/record/418120/files/acs.molpharmaceut.7b01022.pdf
|y Restricted
|z StatID:(DE-HGF)0599
856 4 _ |u https://bib-pubdb1.desy.de/record/418120/files/acs.molpharmaceut.7b01022.gif?subformat=icon
|x icon
|y Restricted
|z StatID:(DE-HGF)0599
856 4 _ |u https://bib-pubdb1.desy.de/record/418120/files/acs.molpharmaceut.7b01022.jpg?subformat=icon-1440
|x icon-1440
|y Restricted
|z StatID:(DE-HGF)0599
856 4 _ |u https://bib-pubdb1.desy.de/record/418120/files/acs.molpharmaceut.7b01022.jpg?subformat=icon-180
|x icon-180
|y Restricted
|z StatID:(DE-HGF)0599
856 4 _ |u https://bib-pubdb1.desy.de/record/418120/files/acs.molpharmaceut.7b01022.jpg?subformat=icon-640
|x icon-640
|y Restricted
|z StatID:(DE-HGF)0599
856 4 _ |u https://bib-pubdb1.desy.de/record/418120/files/acs.molpharmaceut.7b01022.pdf?subformat=pdfa
|x pdfa
|y Restricted
|z StatID:(DE-HGF)0599
856 4 _ |u https://bib-pubdb1.desy.de/record/418120/files/Langguth_RNA_SAXS_review_clean.gif?subformat=icon
|x icon
|y Published on 2017-12-12. Available in OpenAccess from 2018-12-12.
|z StatID:(DE-HGF)0510
856 4 _ |u https://bib-pubdb1.desy.de/record/418120/files/Langguth_RNA_SAXS_review_clean.jpg?subformat=icon-1440
|x icon-1440
|y Published on 2017-12-12. Available in OpenAccess from 2018-12-12.
|z StatID:(DE-HGF)0510
856 4 _ |u https://bib-pubdb1.desy.de/record/418120/files/Langguth_RNA_SAXS_review_clean.jpg?subformat=icon-180
|x icon-180
|y Published on 2017-12-12. Available in OpenAccess from 2018-12-12.
|z StatID:(DE-HGF)0510
856 4 _ |u https://bib-pubdb1.desy.de/record/418120/files/Langguth_RNA_SAXS_review_clean.jpg?subformat=icon-640
|x icon-640
|y Published on 2017-12-12. Available in OpenAccess from 2018-12-12.
|z StatID:(DE-HGF)0510
856 4 _ |u https://bib-pubdb1.desy.de/record/418120/files/Langguth_RNA_SAXS_review_clean.pdf?subformat=pdfa
|x pdfa
|y Published on 2017-12-12. Available in OpenAccess from 2018-12-12.
|z StatID:(DE-HGF)0510
909 C O |o oai:bib-pubdb1.desy.de:418120
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |0 I:(DE-588b)2008985-5
|6 P:(DE-H253)PIP1002601
|a Deutsches Elektronen-Synchrotron
|b 3
|k DESY
913 1 _ |0 G:(DE-HGF)POF3-621
|1 G:(DE-HGF)POF3-620
|2 G:(DE-HGF)POF3-600
|9 G:(DE-HGF)POF3-6215
|a DE-HGF
|b Forschungsbereich Materie
|l Von Materie zu Materialien und Leben
|v In-house research on the structure, dynamics and function of matter
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2018
915 _ _ |0 StatID:(DE-HGF)0200
|2 StatID
|a DBCoverage
|b SCOPUS
915 _ _ |0 StatID:(DE-HGF)1030
|2 StatID
|a DBCoverage
|b Current Contents - Life Sciences
915 _ _ |0 StatID:(DE-HGF)0530
|2 StatID
|a Embargoed OpenAccess
915 _ _ |0 StatID:(DE-HGF)0100
|2 StatID
|a JCR
|b MOL PHARMACEUT : 2017
915 _ _ |0 StatID:(DE-HGF)0150
|2 StatID
|a DBCoverage
|b Web of Science Core Collection
915 _ _ |0 StatID:(DE-HGF)0111
|2 StatID
|a WoS
|b Science Citation Index Expanded
915 _ _ |0 StatID:(DE-HGF)9900
|2 StatID
|a IF < 5
915 _ _ |0 StatID:(DE-HGF)0310
|2 StatID
|a DBCoverage
|b NCBI Molecular Biology Database
915 _ _ |0 StatID:(DE-HGF)1050
|2 StatID
|a DBCoverage
|b BIOSIS Previews
915 _ _ |0 StatID:(DE-HGF)0300
|2 StatID
|a DBCoverage
|b Medline
915 _ _ |0 StatID:(DE-HGF)0199
|2 StatID
|a DBCoverage
|b Clarivate Analytics Master Journal List
920 1 _ |0 I:(DE-H253)HAS-User-20120731
|k DOOR
|l DOOR-User
|x 0
920 1 _ |0 I:(DE-H253)FS-PEX-20130206
|k FS-PEX
|l PETRA III Extension
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-H253)HAS-User-20120731
980 _ _ |a I:(DE-H253)FS-PEX-20130206
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21